Researchers conduct study to identify common genetic architecture of PCOS
PCOS is the most common endocrine disorder found in reproductive-age women, and is a major cause of infertility and type 2 diabetes. The source of the disease is
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will